Myeloperoxidase Inhibitor Screening Kit (F), Catalog: MA-0381

Catalog MA-0381

Size 200 wells

Sample Type Tissue Extracts, Cell Lysates, Urine, Plasma, Serum, Other biological fluids, etc.

Method of Detection Fluorometric, Ex/Em = 480/520 nm or Ex/Em = 535/587 nm

Assay Type Quantitative

Application A simple, sensitive plate-based assay to measure simple sensitive way to assess hypochlorite formation or peroxidation and how inhibitors can affect Myeloperoxidase (MPO) activity. 

Storage Conditions -20°C

Shipping Temperature Gel Pack

Shelf Life One year from the date of delivery

Myeloperoxidase (MPO), produced by neutrophils and, to a lesser extent, monocytes is involved in the innate immune response and pathogenesis of several chronic diseases. MPO is released from activated neutrophils during a "respiratory burst" at sites of infection or inflammation. It catalyzes the conversion of hydrogen peroxide and chloride ion into hypochlorite, a highly reactive oxidant capable of killing pathogens. This function is essential for effective innate immunity. MPO can also modify low-density lipoprotein (promoting uptake by macrophages and contributing to foam cell formation) and high-density lipoprotein (impairing protective functions and promoting vascular inflammation). It catalyzes the formation of tyrosyl radicals and protein nitrosylation, altering protein structure and function and affecting cellular signaling, protein stability and immune recognition. MPO activity is positively correlated with obesity, insulin resistance, and metabolic syndrome and is implicated in the pathogenesis of rheumatoid arthritis, neurodegenerative disease, liver disease, and certain cancers, making it a target for drug development. AkrivisBIo’s Myeloperoxidase Inhibitor Screening Kit is a simple sensitive way to assess hypochlorite formation or peroxidation and how inhibitors can affect MPO activity.